Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Matt,
funny you mention Barclays, one of my largest holdings and it’s done very well. In any case, you are pointing at future prospects. As things stand, I cannot find a test that has been passed. So if the tenders are going out very imminently, then don’t you think you need an approved test in place before you can bid.
Moreover, I cannot find an update where they state it’s been tested on additional samples other than the 56 it’s based on.
Vega,
Isn’t this a discussion board or is it an echo chamber?
Jumbo may I ask why your bothered?
Just been on that Maltese Bank thing looks boring no wonder big ear jumbo is here
Matt apologies wasn't intentional
Matt,
I have and I cannot find any test approval RNS. If the £8 billion is to be bid for, surely the test has to be approved first.
Point to me in any of the RNS jdt1990. Maybe I missed something.
Just stinks of TW sending his goons out Sunday ready for a big couple of weeks ahead.
My response now to any of this cr*p is just two words. VOX INTERVIEW.
Jog on
Energy,
It’s not a share, someone created a place for few of us to discuss shares in a very friendly atmosphere. You are more than welcome to come and put up a case for avct. I am sure there might be someone on there already invested in avct.
Matt and others,
Why all so defensive? I am not talking about merits or demerits of avacta with regards to their pipeline. This is about LFT, Have they got an approved antigen test for use in UK? Yes or no?
Has it even been tested on more than 56 samples?
Dumbo jog on back to Bank Of Valletta Plc
BB your little penny share...
Mumbo Dumbo
Test approved in the next few weeks but have you seen what they have coming through....... :):):):):)
Avacta the new GlaxoThu 15:17
Glaxo’s rise started with one major blockbuster Zantac,which became the worlds largest selling drug, it helped Glaxo into multi mergers with Wellcome and then Smithkline Beecham.
Avacta has the chance to dwarf Glaxo’s rise in the next few years.
Most Biotech stocks have one maybe two drugs or treatments in their pipeline and are often bought out before they get to market.
Avacta has 33 yes 33 chances of a blockbuster product and they are still coming.
Affimer tech can propel Avacta into Blockbuster sales.
Major Pharms & Diagnostics firms have licences and products with Avacta
Daewoong,Moderna,LG Chem,Bruker,ADC,Point,
Astrea,Mologic,Deepverge,Tufts, the more companies that licence affimers the harder and more costly it will be to buy out Avacta.
Oncology x 11
Ava6000,AVA7500,
AVA028,AVA7000,AVA004
AVA027,AVA3996 plus 4 undisclosed targets
Covid x 5
Affidx, Bams,Elisa,
Saliva,Spitaffidx (You can have that one Big Al)
Mologic combination test.
Plus in house pipe line non-COVID diagnostic tests, which include assays for D-dimer, cortisol, vitamins D and B12 and CRP.
LG Chem x 8
Every RNS states a multi-target deal with LG Chem worth up to $400m.
In the business update $98 million for the 2 below and up to $55m for each new product
So LG Chem has potentially 8 new products.
multi-target collaboration with LG Chem incorporating Avacta's Affimer XT™ serum half-life extension and LG Chem has Affimer PD-L1 inhibitortotalling $98million
The expanded partnership also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn an additional $55m in milestone payments for each of these new products.
Daewoong x 2
Gene & stem cell with other targets
Point x 1
radiopharmaceutical prodrug
ADC x 3
three undisclosed cancer targets and provide these to ADC Therapeutics
Moderna x 1
exclusive license agreement with respect to certain Affimer molecules
Astrea x 1
Deepverge x 1
My ISA maxed loaded and waiting for the fireworks.
:)
As far as I can see, nothing has changed and antigen test still not approved... then where is this talk of bidding for £8 billion coming from?
There is no data other than the 56 samples they used.
They did try it at porton down..............
Let’s broaden this out, has any UK company got a LFT test approved yet?